Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bessy Benejam

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Nature Communications|July 15, 2021
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndromeAlberto Lleó, Henrik Zetterberg, Jordi Pegueroles, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2026
Factors impacting survival in individuals with Down syndrome-associated Alzheimer's diseaseBessy Benejam, Mary McCarron, María Carmona-Iragui, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 21, 2025
Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuumNatalia Valle-Tamayo, Mateus Rozalem Aranha, Rocío Pérez-González, et al.
Ebiomedicine|July 11, 2026
CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuumJavier Arranz, Juan Lantero-Rodríguez, Luisa Sophie Braun-Wohlfahrt, et al.
The Lancet. Neurology|June 16, 2016
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trialRafael de la Torre, Susana de Sola, Gimena Hernandez, et al.
Nature Communications|November 10, 2025
Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndromeHanna Huber, Javier Arranz, Burak Arslan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 19, 2025
Study of brain perfusion in adults with Down syndrome along the Alzheimer's disease continuumMaria Franquesa-Mullerat, Alejandra O Morcillo-Nieto, José Enrique Arriola-Infante, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 3, 2025
Impact of Alzheimer's disease on sleep in adults with Down syndromeSandra Giménez, Lídia Vaqué-Alcázar, Nuole Zhu, et al.
Annals of Neurology|March 14, 2025
Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down SyndromeJosé Enrique Arriola-Infante, Alejandra O Morcillo-Nieto, Sara E Zsadanyi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 3, 2017
Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's diseaseMaría Carmona-Iragui, Mircea Balasa, Bessy Benejam, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Nature Communications|July 15, 2021
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndromeAlberto Lleó, Henrik Zetterberg, Jordi Pegueroles, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2026
Factors impacting survival in individuals with Down syndrome-associated Alzheimer's diseaseBessy Benejam, Mary McCarron, María Carmona-Iragui, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 21, 2025
Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuumNatalia Valle-Tamayo, Mateus Rozalem Aranha, Rocío Pérez-González, et al.
Ebiomedicine|July 11, 2026
CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuumJavier Arranz, Juan Lantero-Rodríguez, Luisa Sophie Braun-Wohlfahrt, et al.
The Lancet. Neurology|June 16, 2016
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trialRafael de la Torre, Susana de Sola, Gimena Hernandez, et al.
Nature Communications|November 10, 2025
Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndromeHanna Huber, Javier Arranz, Burak Arslan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 19, 2025
Study of brain perfusion in adults with Down syndrome along the Alzheimer's disease continuumMaria Franquesa-Mullerat, Alejandra O Morcillo-Nieto, José Enrique Arriola-Infante, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 3, 2025
Impact of Alzheimer's disease on sleep in adults with Down syndromeSandra Giménez, Lídia Vaqué-Alcázar, Nuole Zhu, et al.
Annals of Neurology|March 14, 2025
Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down SyndromeJosé Enrique Arriola-Infante, Alejandra O Morcillo-Nieto, Sara E Zsadanyi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 3, 2017
Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's diseaseMaría Carmona-Iragui, Mircea Balasa, Bessy Benejam, et al.
Pageof 8